After moving -3.5% during today's afternoon session, Bristol-Myers Squibb Company is now trading at a price of $49.05 per share. On average, analysts give it a target price of $58.03.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Potential Bristol-Myers Squibb Company Investors Should Analyze the Following:
-
Bristol-Myers Squibb Company has moved -37.0% over the last year.
-
The company has a price to earnings growth (PEG) ratio of -31.96. A number between 0 and 1 could mean that the market is undervaluing Bristol-Myers Squibb Company's estimated growth potential
-
Its Price to Book (P/B) ratio is 3.44
-
Bristol-Myers Squibb Company currently returns an annual dividend yield of 4.5%.
Understanding Bristol-Myers Squibb Company's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 45,187,000 | 36,490,000 | 19 | 11.76 |
| 2022 | 46,159,000 | 38,446,000 | 17 | 0.0 |
| 2021 | 46,385,000 | 38,287,000 | 17 | 206.25 |
| 2020 | 42,518,000 | 49,389,000 | -16 | -184.21 |
| 2019 | 26,145,000 | 21,170,000 | 19 | -26.92 |
| 2018 | 22,561,000 | 16,593,000 | 26 |
Over the last 6 years, Bristol-Myers Squibb Company's operating margins have averaged 13.7%, which is similar to the 12.02% Pharmaceutical industry average. We also note that the company's operating margins have a high coefficient of variability at 1017.3%. The firm's margins exhibit a relatively stable growth trend of -4.9%.
